| Treatment options in metastatic renal cell carcinoma: Focus on mTOR inhibitors ... - UroToday |
|
|
UroTodayThe agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: (1) vascular endothelial growth ...A phase II study of tandutinib (MLN518), a selective inhibitor of type III ... read more |